

The Nomination Committee's proposal for the annual general meeting 2024

The Nomination Committee of Egetis Therapeutics AB (publ), reg. no. 556706-6724, (the “**Company**”) has been appointed in accordance with the principles adopted by the annual general meeting 2023 and consists of James Brush (Chairman), appointed by Frazier Life Sciences, Peter Lindell, appointed by Cidro Förvaltning AB and Peder Walberg, appointed by Cetoros AB. The Chairman of the Board, Thomas Lönngren, has been co-opted to the Nomination Committee's meeting and has otherwise been in close dialog with the Nomination Committee.

The composition of the Nomination Committee was announced on November 1, 2023 and has been available on the Company's website. The members of the Nomination Committee have been appointed by shareholders who together represent approximately 35 percent of the shares and votes in the Company.

In accordance with the principles adopted by the annual general meeting 2023, the Nomination Committee makes the following proposals for the annual general meeting on May 6, 2024.

Chairman of the annual general meeting

The Nomination Committee proposes that attorney-at-law Dain Hård Nevenon is elected as Chairman of the annual general meeting.

Number of members of the Board and auditors

The Nomination Committee proposes that the number of members of the Board is to be five, with no deputy members, and the number of auditors is to be one registered public accounting firm.

Remuneration to the Board members and the auditor

The Nomination Committee proposes that the Board's remuneration for the time until the next annual general meeting shall remain unchanged and amount according to the following (brackets indicate the remunerations for the current year):

- Chairman of the Board: SEK 630,000 (630,000)
- Other Board members not employed by Egetis: SEK 235,000 (235,000)

It is proposed that no remuneration is to be paid to Board members who are employed by Egetis.

Furthermore, it is proposed that the following remuneration is to be paid for committee work for the period until the next annual general meeting:

Chairman of the Audit Committee: SEK 80,000 (80,000)
Member of the Audit Committee: SEK 40,000 (40,000)
Chairman of the Remuneration Committee: SEK 50,000 (50,000)
Member of the Remuneration Committee: SEK 25,000 (25,000)
Chairman of the Market Access Committee: SEK 80,000 (80,000)
Member of the Market Access Committee: SEK 40,000 (40,000)

The proposal entails a total remuneration to the Board amounting to SEK 1,885,000 (2,120,000).

The Nomination Committee further proposes that the remuneration to the auditor shall be paid against approved invoice.

Election of the Board of Directors

The Nomination Committee has taken part of the Board evaluation and has been in contact with all Board members. The Nomination Committee proposes re-election of the Board members Thomas Lönngren, Mats Blom, Gunilla Osswald, Behshad Sheldon and Peder Walberg.

The Board member Elisabeth Svanberg has declined re-election.

No deputies are proposed to be elected.

Furthermore, the Nomination Committee proposes re-election of Dr. Thomas Lönngren as Chairman of the Board.

The Nomination Committee assesses that the composition of the Board of Directors meets the requirements for independence set out in the Swedish Corporate Governance Code. The Nomination Committee's motivated statement regarding the proposal for the election of the Board of Directors is presented in Appendix 1.

Election of auditor

The Nomination Committee proposes re-election of the registered auditing firm Öhrlings PricewaterhouseCoopers AB (PwC) as auditor of the Company for a term of office extending until the end of the next annual general meeting. PwC has informed that authorized public accountant Niclas Bergenmo shall be the auditor in charge and replace Leonard Daun.

Instructions for the work of the Nomination Committee

The Nomination Committee proposes that the annual general meeting resolves to adopt the instructions for the work of the Nomination Committee set out below.

Principles for appointing the members of the Nomination Committee

The general meeting authorizes the Chairman of the Board of Directors to contact the three largest shareholders according to Euroclear Sweden AB's transcription of the share register as of September 30, 2024, each of them appointing a member of the Nomination Committee. In addition, the Chairman of the Board shall, if desired by the members of the Nomination Committee, be co-opted to the Nomination Committee's meetings.

In the event that any of the three largest shareholders does not wish to appoint a member of the Nomination Committee the fourth largest shareholder should be asked and so forth, until the Nomination Committee consists of three members. However, if several shareholders waive their right to appoint a member to the Nomination Committee, no more than the ten largest shareholders need to be consulted.

The composition of the Nomination Committee shall be announced on the Company's website no later than six months prior to the next annual general meeting.

The term of office of the appointed Nomination Committee shall run until a new Nomination Committee has been appointed under a mandate from the next annual general meeting.

Should a shareholder having appointed a representative to the Nomination Committee no longer be among the three largest shareholders at a point in time falling three months before the annual general meeting at the latest, the representative appointed by such shareholder

shall resign and the shareholder who is then among the three largest shareholders shall have the right to appoint one representative to the Nomination Committee. Unless there are specific reasons otherwise, the already established composition of the Nomination Committee shall, however, remain unchanged in case such change in the ownership is only marginal or occurs during the three-month period prior to the annual general meeting. Where a shareholder has become one of the three largest shareholders due to a material change in the ownership at a point in time falling later than three months before the annual general meeting, such shareholder shall however in any event have the right to appoint a representative who shall have the right to take part of the work of the Nomination Committee and participate at its meetings.

If a member leaves the Nomination Committee before its work is completed and the Nomination Committee finds that there is a need for replacing this member, the Nomination Committee shall appoint a new member in accordance with the principles described above, but based on Euroclear Sweden AB's transcription of the share register as soon as possible after the member left the Nomination Committee. Any change in the composition of the Nomination Committee shall be announced immediately.

The assignment of the Nomination Committee

The Nomination Committee shall prepare and present proposals regarding the following items for the annual general meeting 2025:

- a) Election of Chairman of the meeting,
- b) Resolution on the number of members of the Board of Directors,
- c) Resolution on the remuneration to the Board of Directors, divided between the Chairman and other members,
- d) Resolution on the remuneration to the auditors,
- e) Election of members of the Board of Directors and Chairman of the Board of Directors,
- f) Election of auditors, and
- g) Proposal for principles for the composition and instructions regarding work of the Nomination Committee

When preparing the proposal regarding the election of members of the Board of Directors and Chairman of the Board of Directors, the Nomination Committee shall apply section 4.1 of the Swedish Corporate Governance Code (the "Code") as a diversity policy.

The Nomination Committee shall otherwise perform the tasks assigned to the Nomination Committee in accordance with the Code.

The work of the Nomination Committee

The Nomination Committee appoints the Chairman of the committee.

The Nomination Committee shall meet as often as is necessary for the Nomination Committee to fulfil its duties, but at least once per year. Notices convening meetings are issued by the Chairman of the Nomination Committee. If a member requests that the Nomination Committee be convened, the request shall be complied with.

The Nomination Committee is quorate if at least two members are present. Resolutions of the Nomination Committee shall be adopted by a simple majority of the members present or, in the event of a tied vote, the Chairman shall have the casting vote.

Minutes shall be kept at the Nomination Committee's meetings.

Remuneration

No remuneration shall be paid to the members of the Nomination Committee. However, any necessary and reasonable expenses incurred in connection with the Nomination Committee's work shall be borne by the Company.

Stockholm, March 2024

The Nomination Committee of Egetis Therapeutics AB (publ)

Annex 1. The Nomination Committee's motivated statement regarding the proposal for the election of the Board of Directors for the annual general meeting 2024

Report on the work of the Nomination Committee during the year

Within the framework of its work for the annual general meeting 2024, the Nomination Committee has held three meetings at which minutes were recorded, as well as written and oral communication both before and after the meetings of the Nomination Committee. The Chairman of the Board was co-opted to the Nomination Committee's meetings and the communication, but did not participate in the decision on the Nomination Committee's recommendation on the remuneration to the Board members. The Nomination Committee has also had direct contact with all members of the Board of Directors and certain members of the management of the Company. As a basis for its work, the Nomination Committee has, among other things, conducted an annual evaluation of the Board's work that has been carried out. The evaluation focuses on the Board's working methods, its working climate and the need for special Board competence. The Nomination Committee has noted that the Board members' commitment as well as the frequency of attendance have been high, and that the Board's work has functioned well during the past mandate period.

Shareholders have had the opportunity to submit proposals to the Nomination Committee.

The Nomination Committee's motivated statement regarding the proposal for the election of the Board of Directors

The starting point for the Nomination Committee's work is that the Board of Directors shall have an appropriate composition with regard to the Company's operations, stage of development and other circumstances, characterized by versatility and breadth of the Board members' competence, experience and background. The Nomination Committee has in particular taken into account the need for industry experience and other relevant competence in order to successfully drive the Company's continued development and strategy. Independence issues have also been highlighted as well as the issue of diversity and a balanced gender distribution.

The Nomination Committee is of the opinion that the proposed Board is well functioning. The proposed Board members have solid experience of the life science industry and other expertise in medicine, research, regulatory issues, pharmaceutical product launch, finance, management and business development. Several of the proposed members also have experience of Board work in listed companies and the special requirements imposed on such companies. The Nomination Committee considers that the proposed Board of Directors has an appropriate experience, competence and breadth. The Nomination Committee has also assessed that the members have the time and availability required to perform the assignment as a Board member in a satisfactory manner.

In an assessment of the proposed Board members' independence, the Nomination Committee has found that its proposal for the Board of Directors of the Company meets the requirements for independence set out in the Code. The Nomination Committee makes the assessment that Peder Walberg, Board member and performer of certain operational tasks in the Company and representative of the second largest shareholder Cetoros AB, is dependent in relation to the Company, the management and the Company's major shareholders. The other four members are independent both in relation to the Company and its management and in relation to the Company's major shareholders.

Against the above background, the Nomination Committee considers that the proposed Board of Directors has an appropriate composition with regard to the Company's

operations, stage of development and other circumstances.

Information on all proposed Board members is available on Egetis Therapeutics' website www.egetis.com.